

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

Post-Effective Amendment No. 1  
to  
FORM S-3  
REGISTRATION STATEMENT

UNDER  
THE SECURITIES ACT OF 1933

**NAVIDEA BIOPHARMACEUTICALS, INC.**  
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**2835**  
(Primary Standard Industrial  
Classification Code Number)

**31-1080091**  
(I.R.S. Employer  
Identification Number)

**4995 Bradenton Avenue, Suite 240**  
**Dublin, Ohio 43017**  
**(614) 793-7500**

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)

**Michael S. Rosol, Ph.D.**  
**Chief Medical Officer**  
**Navidea Biopharmaceuticals, Inc.**  
**4995 Bradenton Avenue, Suite 240**  
**Dublin, Ohio 43017**  
**(614) 793-7500**

(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)

*Copies to:*  
**Martin R. Rosenbaum, Esq.**  
**William M. Mower, Esq.**  
**Maslon LLP**  
**90 South 7<sup>th</sup> Street, Suite 3300**  
**Minneapolis, MN 55402**

**Approximate date of commencement of proposed sale to the public:** Not Applicable

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box:

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the "Securities Act"), check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

---

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the U.S. Securities and Exchange Commission pursuant to Rule 462(e) under the Securities Act, check the following box.

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Non-accelerated filer

Emerging growth company

Accelerated filer

Smaller reporting company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

---

---

## DEREGISTRATION OF SECURITIES

On April 27, 2011, Navidea Biopharmaceuticals, Inc. (the "Company") filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission, Registration Number 333-173752 (the "Registration Statement"), to register (i) an indeterminate number of shares of the Company's common stock, shares of the Company's preferred stock, warrants, subscription rights, purchase contracts, and units as would have an aggregate initial offering price not to exceed \$100,000,000 ("Primary Offering") and (ii) the resale by the selling stockholder named in the Registration Statement of up to 12,500,000 shares of common stock of the Company ("Secondary Offering"). The Registration Statement was declared effective on May 9, 2011.

On May 8, 2014, the Company filed a registration statement on Form S-3, Registration Statement No. 333-195806 ("2014 Registration Statement"), to register new securities and to carry forward to the 2014 Registration Statement the unsold securities previously registered for the Primary Offering under the Registration Statement pursuant to Rule 415(a)(6) under the Securities Act.

The Company is filing this Post-Effective Amendment No. 1 to the Registration Statement to deregister all of the shares of the Company's common stock that have not been sold in the Secondary Offering pursuant to the Registration Statement as of the date hereof, as the Company does not have a contractual obligation to maintain the effectiveness of the Registration Statement. Pursuant to the Company's undertaking in Part II, Item 17(a)(3) of the Registration Statement, the Company hereby amends the Registration Statement to remove from registration all shares of Common Stock registered for the Secondary Offering that remain unsold.

---

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, State of Ohio, on the 18th day of May, 2022.

### NAVIDEA BIOPHARMACEUTICALS, INC.

By /s/ Michael S. Rosol  
Michael S. Rosol, Ph.D.  
Chief Medical Officer (Principal Executive Officer)

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

<b>Signature</b>	<b>Title</b>	<b>Date</b>
<u>/s/ Michael S. Rosol</u> Michael S. Rosol, Ph.D.	Chief Medical Officer (Principal Executive Officer)	May 18, 2022
<u>/s/ Erika L. Eves</u> Erika L. Eves	Vice President, Finance & Administration (Principal Financial Officer and Principal Accounting Officer)	May 18, 2022
<u>/s/ Alexander L. Cappello</u> Alexander L. Cappello	Chairman of the Board of Directors	May 18, 2022
<u>/s/ John K. Scott, Jr.</u> John K. Scott, Jr.	Vice Chairman of the Board of Directors	May 18, 2022
<u>/s/ Amit Bhalla</u> Amit Bhalla	Director	May 18, 2022
<u>/s/ Malcolm G. Witter</u> Malcolm G. Witter	Director	May 18, 2022